Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $34 | $0 |
| % Growth | 48.4% | -99.8% | 105,767.6% | – |
| Gross Profit | $0 | $0 | $17 | $0 |
| % Margin | 47.7% | 46.5% | 48.6% | 45.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 3.4% | 4.5% | 0% | 20.1% |
| Net Income | -$0 | $0 | $4 | $0 |
| % Margin | -5.1% | 35.5% | 12.9% | 27.6% |
| EPS Diluted | -0.004 | 0.02 | 4.35 | 0.007 |
| % Growth | -120.3% | -99.5% | 58,683.8% | – |
| Operating Cash Flow | $0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | $0 |